Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

77.64EUR
11:35am EDT
Change (% chg)

€0.14 (+0.18%)
Prev Close
€77.50
Open
€77.60
Day's High
€78.30
Day's Low
€77.40
Volume
281,936
Avg. Vol
335,117
52-wk High
€78.30
52-wk Low
€56.55

Select another date:

Mon, Aug 13 2018

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

BRIEF-Cimzia Is The First Therapy To Demonstrate Positive Results In A 52-Week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

* CIMZIA® (CERTOLIZUMAB PEGOL) IS THE FIRST THERAPY TO DEMONSTRATE POSITIVE RESULTS IN A 52-WEEK, PLACEBO CONTROLLED NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STUDY

BRIEF-UCB Announces Positive CHMP Opinion For Cimzia®

* UCB ANNOUNCES POSITIVE CHMP OPINION FOR CIMZIA® (CERTOLIZUMAB PEGOL) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

BRIEF-UCB Q1 Revenue Down At 1.07 Billion Euros

* FINANCIAL OUTLOOK 2018 CONFIRMED: REVENUE EXPECTED TO REACH € 4.5 - 4.6 BILLION

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

BRIEF-UCB SA U.S. Food And Drug Administration (FDA) Approves Label Change For UCB’S Cimzia®

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®

BRIEF-UCB FY Net Sales Up At ‍​4.18 Billion Euros

* FY: REVENUE EUR 4.53‍​ BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR ‍​4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO

Select another date: